Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Elisabethann Wright
AI Uses During Lifecycle Of Medicinal Products And Medical Devices: An EU Regulatory Perspective
Analysis Executive Summary Despite expectations in some circles in December 2023 that adoption of the EU AI Act was imminent, the scope of the final text and when it will be published remain unclear. There are, however, related consequences that can be anticipated. Existing Subscriber? Sign in to continue reading. New to In Vivo? Start a free trial today!
Medical Devices Regulation - Life Sciences, Biotechnology & Nanotechnology - European Union
The EU Medical devices Regulation Cooley's Productwise Bitesize brings you a short overview of the EU Medical Devices Regulation. What is it called? The Medical Devices Regulation (MDR Regulation (EU) 2017/745) governs the placing on the market in the European Economic Area (EEA) of medical devices and its accessories as well as clinical investigations taking place in the EEA.
European Union February 4 2022 On 14 January 2022, the European Commission published a draft Implementing Regulation laying down the Common Specifications for the groups of products without an intended medical purpose that are listed in Annex XVI of the Medical Device Regulation (“MDR”). The proposal would establish technical and clinical requirements that these products must fulfil to demonstrate compliance with the MDR.
Productwise Bitesize: Clinical Trials Regulation
To print this article, all you need is to be registered or login on Mondaq.com. The EU Clinical Trials Regulation's transitional period Cooley's Productwise Bitesize brings you a short overview of the transitional provisions in the new Clinical Trials Regulation. What is it called? On 31 January 2022, Regulation (EU) 536/2014 on clinical trials on medicinal products for human use (the “Clinical Trials Regulation”) will become applicable in the EU.
Post-Brexit drug shortages: Over-exaggeration or reality?
This week, a group that represents U.K. hospitals and ambulance services has said that its members may run out of drugs if Britain leaves the European Union without an agreement on future relations. Pharma Logistics IQ wanted to dig deeper into those claims, so we spoke to Elisabethann Wright, Partner at Hogan Lovells and Jane Summerfield Counsel at Hogan Lovells. Both are experts in regulatory issues on EU Life Sciences Law.
Will there be drug shortages post-Brexit?
Back in July, there were multiple stories suggesting Brexit will lead to drug shortages. Pharma Logistics IQ wanted to dig deeper into those claims, so we spoke to Elisabethann Wright, Partner at Hogan Lovells and Jane Summerfield Counsel at Hogan Lovells. Both are experts in regulatory issues on EU Life Sciences Law.
The European Commission issues guidance concerning management of legacy devices in EUDAMED | JD Supra
On 15 February 2021, the European Commission published guidance on the Management of legacy devices in EUDAMED. This guidance complements the guidance concerning the registration of legacy devices in EUDAMED issued by the European Commission on 15 April 2019.
COVID-19 Report for Life Sciences and Health Care Companies (UPDATED) | JD Supra
The COVID-19 Report is a compilation of coronavirus news, analysis, and insights from around the world to help life sciences and health care companies stay current in this challenging time. In Tuesday's Report: European Commission proposes far-reaching pharmaceutical strategic plan, Biden names health care nominees, and warnings over Christmas COVID-19 spread. Tuesday, 8 December 2020 On 25 November 2020, the European Commission published a proposal for a new Pharmaceutical Strategy for Europe.
The European Commission proposes a new Pharmaceutical Strategy for the EU | JD Supra
[co-author: Silvia Lopez Arnao] On 25 November 2020, the European Commission published a proposal for a new Pharmaceutical Strategy for Europe (“the Strategy”). The Strategy is built around four main objectives, each with an assigned work strand. It proposes concrete actions to ensure accessibility, availability, and affordability of innovative medicinal products. The proposal is also intended to support a competitive and innovative pharmaceutical industry in the EU.
EC working group provides guidance concerning COVID-19 product claims on cosmetic products | JD Supra
[co-author: Silvia López Arnao] On 12 November 2020, the European Commission’s Sub-Working Group on Borderline Products published a technical document concerning product claims related to leave-on hydro alcoholic hand gels within the context of COVID-19 pandemic. This technical document provides a list of product claims which would not support the classification of leave-on hydro alcoholic hand gels as cosmetic products.
EMA publishes list of COVID-19 treatments that have been the subject of the Agency’s guidance | JD Supra
[co-author: Silvia López Arnao] On 30 October 2020, the European Medicines Agency (“EMA”) published a list containing all COVID-19 treatments and vaccines that have so far been the subject of scientific advice or informal guidance from EMA’s pandemic Task Force. This initiative is part of the EMA’s efforts to implement extra transparency measures in relation to the review of COVID-19 medicinal products.
EMA and HTA bodies jointly review a proposed EU framework for patient preference studies | JD Supra
[co-author: Silvia Lopez Arnao] The European Medicines Agency (“EMA”) and the EU network of Health Technology Assessment (“HTA”) bodies are jointly reviewing a proposed framework for patient preference studies. The intention of the proposed framework is to provide recommendations to support the development of guidelines concerning the inclusion of patient preferences on the benefit-risk assessment of medicinal products and medical devices.
The EMA intends to update the Guidance concerning Additional Risk Minimisation Measures | JD Supra
[co-author: Silvia López Arnao] The European Medicines Agency (“EMA”) has announced its intention to update the Agency’s existing guidance concerning additional risk minimisation measures (“aRMMs”). The revised version will provide extensive guidance on various tools for additional risk minimization. Some of these were already mentioned in the current version of the guidance. Others will be introduced by the revised version.
The EMA has published guidance on registry-based studies as a tool to generate RWE | JD Supra
[co-author: Silvia López Arnao] On 24 September 2020, the European Medicines Agency (“EMA”) published a draft Guideline on registry-based studies. The EMA’s intention is to enhance the use of registry-based studies as a source of real-world evidence (RWE). The guideline is primarily aimed at marketing authorization applicants and holders planning to conduct registry studies in the pre- or post-marketing authorization phase.
Genetically modified soybean authorised by the European Commission for food and feed use | JD Supra
[co-author: Silvia Lopez Arnao] On 28 September 2020, the European Commission authorized a genetically modified organism (GMO) for food and feed use: the glyphosate resistant soybean MON 87708 x MON 89788 x MON A5547-127. The authorization of these genetically modified soybeans followed a favourable risk assessment by the European Food Safety Authority (EFSA). The decision is valid for 10 years. The authorization does not permit cultivation of the GMO soybeans in the EU.
The EMA plans to grant early access to a test version of the CTIS | JD Supra
[co-author: Silvia Lopez Arnao] On 21 September 2020, the European Medicines Agency (“EMA”) announced its plan to provide access to a test version of the Clinical Trials Information System (“CTIS”) by mid-2021. Potential users will have access to an isolated and secured testing environment of the CTIS, called “sandbox". The elements of the system include guidance from the EMA on how to access the system and how to submit a clinical trial application.
Belgian Data Protection Authority publishes guidance concerning Schrems II | JD Supra
[co-author: Silvia Lopez Arnao] The Belgian Data Protection Authority (DPA) has published brief guidance concerning the European Court of Justice (ECJ) judgement on the European Commission’s adequacy decision provided by the EU-US data Privacy Shield (Schrems II).
EU Commission adopts Communication on Brexit including anticipated changes in the health sector | JD Supra
[co-author: Vicky Vlontzou] On 9 July 2020 the European Commission adopted a Communication regarding readiness at the end of the transition period between the European Union and the United Kingdom. The Communication sets out a sector-by-sector overview of the main areas where changes are anticipated regardless of the outcome of the ongoing EU-UK negotiations. It also sets out measures that national authorities, businesses and citizens should take in order to prepare for these changes.
EU Clinical Trials Regulation to apply from December 2021 | JD Supra
[co-author: Vicky Vlontzou] On 12 June 2020, the management board of the European Medicines Agency (EMA) announced December 2021 as the date of entry into application of the EU Clinical Trials Information System (CTIS). This date is slightly earlier than was anticipated. It means that the Clinical Trials Regulation (CTR) may finally begin to apply. On 12 June 2020, the management board of the European Medicines Agency's announced its proposal to set December 2021 as the date of application of CTIS.
CJEU: pharmaceutical companies may not distribute free samples of medicinal products to pharmacists | JD Supra
[co-author: Vicky Vlontzou] On 11 June 2020, the Court of Justice of the European Union (CJEU) delivered a judgement in case C-786/18 GmbH v. Novartis Consumer Health GmbH. The judgment followed a request for a preliminary ruling by the German Federal Court of Justice regarding whether pharmaceutical companies may distribute free samples of medicinal products to pharmacists.
CJEU: pharmaceutical companies may not distribute free samples of medicinal products to pharmacists | Lexology
European Union, Germany
June 26 2020 On 11 June 2020, the Court of Justice of the European Union (CJEU) delivered a judgement in case C-786/18 GmbH v. Novartis Consumer Health GmbH. The judgment followed a request for a preliminary ruling by the German Federal Court of Justice regarding whether pharmaceutical companies may distribute free samples of medicinal products to pharmacists.
Belgian DPA Issues Guidance on Temperature Measurements in the Context of COVID-19
In the context of their return-to-work policies companies are seeking solutions to detect individuals with fever at the entrance of their premises with the aim of preventing further contamination within the buildings. This can be achieved by means of conventional thermometers, digital fever scanners directed at the forehead of the person, or sophisticated thermal camera systems.
Belgian DPA Issues Guidance on Temperature Measurements in the Context of COVID-19 | JD Supra
In the context of their return-to-work policies companies are seeking solutions to detect individuals with fever at the entrance of their premises with the aim of preventing further contamination within the buildings. This can be achieved by means of conventional thermometers, digital fever scanners directed at the forehead of the person, or sophisticated thermal camera systems.
Belgian DPA Issues Guidance on Temperature Measurements in the Context of COVID-19
In the context of their return-to-work policies companies are seeking solutions to detect individuals with fever at the entrance of their premises with the aim of preventing further contamination within the buildings. This can be achieved by means of conventional thermometers, digital fever scanners directed at the forehead of the person, or sophisticated thermal camera systems.
EMA offers simultaneous review of products for EU and non-EU markets | JD Supra
The Committee for Medicinal Products on Human Use (CHMP) has announced in the minutes of its Organizational Matters (ORGAM) meeting of 17 February 2020, which were published on 7 May 2020, that it has adopted the EMA proposal for the simultaneous submission and assessment of EU centralized marketing authorization applications (MMAs) and applications for a scientific opinion under Article 58 of Regulation (EC) 726/2004 on the authorization and supervision of medicinal products for human and...
The AFMPS further extends measures to combat shortages of medicinal products by another month | JD Supra
[co-author: Vicky Vlontzou] On 29 May 2020, the AFMPS issued a new decision which further extends the measures initially provided in the Decision 1 April 2020 concerning supply of specific medicinal products by another month. These measures were previously extended until 1 June 2020. The new Decision also provides for the relaxation of some of the measures that were previously imposed.
The AFMPS issues third version of the Alternative Test Protocol for surgical face masks | JD Supra
[co-author: Vicky Vlontzou] On 3 June 2020, the AFMPS issued the third version of the Agency’s alternative test protocol (ATP) for surgical face masks. The alternative test protocol was initially published on 14 April 2020, and allowed masks that had not undergone a conformity assessment procedure in accordance with applicable standards to be placed on the Belgian market. The purpose of this protocol is to facilitate the supply of face masks during the COVID-19 pandemic.
European Commission issues guidance on lawful placing on the market of PPE and medical devices | JD Supra
Applicable regulatory framework The guidance recalls that medical devices and PPE are regulated by the following EU legislation: The Directive 90/385/EEC on active implantable medical devices (AIMDD); The Directive 93/42/EEC on medical devices (MDD); The Directive 98/79/EEC on in vitro diagnostic medical devices (IVDD); Regulation (EU) 745/2017 on medical devices (MDR) (which shall be fully applicable as from 26 May 2021); Regulation (EU) 746/2017 on in vitro diagnostic medical devices (IVDR)...
AFMPS recalls the risks associated with the use of chloroquine and hydroxychloroquine | JD Supra
On 25 May 2020, the AFMPS published a note in which it recalled the risks associated with the use of chloroquine and hydroxychloroquine in the treatment of COVID-19 patients. The note followed a retrospective analysis published by the medical journal "The Lancet" on 22 May 2020. The analysis did not show any benefits to patients with COVID-19 and revealed the occurrence of cardiovascular adverse events.
EMA publishes guidance providing regulatory adaptations for MAHs in the context of COVID-19 | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
AFMPS issues Circular allowing hospitals to reprocess single-use devices | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Belgian AFMPS abolishes quota previously imposed on paracetamol-based medicines | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
The Belgian AFMPS warns about risk of hemolysis associated with the use of hydroxychloroquine | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
New European Commission's guidance document on medical devices and IVDs in the COVID-19 context | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
COVID-19- AFMPS reviews its export ban on certain medicinal products outside the EEA | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Belgium follows the FDA's approach on the reprocessing of surgical masks and FFP2/FFP3 facemasks | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
European Commission announced its plan to postpone the implementation of the MDR by one year | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Belgium temporarily bans the making available and use of rapid COVID-19 IVD self-tests | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Belgian AFMPS latest guidance in the context of COVID-19 outbreak | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
COVID-19- European Commission's recommendation on conformity assessment and market surveillance procedures | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
European Commission publishes new documents regarding the Clinical Trials Regulation | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
European Commission publishes new documents regarding the Clinical Trials Regulation
1. Introduction Shortly after updating the related draft Questions and Answers document (see our blog), the European Commission has published two new documents concerning the Clinical Trials Regulation (EU) 536/2014. The first document is an informed consent and patient recruitment procedure template. The second document is an updated clinical trial Application Form. 2.
Use of ethanol in medicinal products: European Medicines Agency publishes guidance concerning safety information for the package leaflet | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Use of ethanol in medicinal products: European Medicines Agency publishes guidance concerning safety information for the package leaflet
1. Introduction On 22 November 2019, the European Medicines Agency (“EMA”) published an updated Annex to the European Commission’s Guidelines concerning excipients in the labelling and package leaflet of medicinal products for human use. This updated Annex provides a list of the excipients for which specific information should appear in the package leaflet. The list includes Ethanol.
European Commission provides clarification regarding the implementation of the Clinical Trials Regulation | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
European Commission provides clarification regarding the implementation of the Clinical Trials Regulation
1. Introduction The European Commission has published an updated Questions and Answers document concerning the Clinical Trials Regulation (EU) 536/2014. The document provides clarification regarding the implementation of the rules governing clinical trials within the Regulation. The draft document has been submitted for discussion to the Expert Group on Clinical Trials. 2. Clinical Trials Regulation The Clinical Trials Regulation is intended to replace the Clinical Trials Directive 2001/20/EC.
Heads of Medicines Agencies publishes practical guidance on nitrosamines | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
European Medicines Agency’s new guide on the wording of therapeutic indication | JD Supra
Updated: May 25, 2018: JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
European Medicines Agency's new guide on the wording of therapeutic indication
1. Introduction On 21 October 2019, the European Medicines Agency (EMA) published a guide for assessors of centralised applications for marketing authorisation. The guide focuses on the wording used in therapeutic indications. The therapeutic indication is the primary information concerning the use of a medicinal product. The guide provides that therapeutic indications should clearly state the disease/condition and population that a medicinal product is intended to treat.
Heads of Medicines Agencies publishes practical guidance on nitrosamines
1. Introduction In late October 2019, the Co-ordination Group for Mutual Recognition and Decentralised procedures – Human (CMDh) of the Heads of Medicines Agencies (HMA) published a practical guidance on nitrosamines. The guidance is addressed to marketing authorisations holders (MAHs) of products medicinal products authorised nationally in the EU Member States and through the mutual recognition and decentralised procedures.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Elisabethann
Contact Elisabethann, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack